12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-TTRsc: Phase I data

Top-line data from a double-blind, U.K. Phase I trial showed that subcutaneous ALN-TTRsc led to significant knockdown of serum TTR protein levels of >80% vs. placebo (p<0.01), a secondary endpoint. ALN-TTRsc was well tolerated. The trial is enrolling up to 40 healthy volunteers to receive single doses of 1.25, 2.5, 5 or...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >